Recent studies have explored various strategies for developing effective aldose reductase inhibitors (ARIs) that can selectively target this enzyme while minimizing side effects. Recent research ...

An investigational aldose reductase inhibitor (ARI), govorestat is being developed for treating several rare diseases. The NDA is supported by data demonstrating a quick and lasting decline in ...

The Company's lead drug candidate, AT-007, is a novel central nervous system penetrant aldose reductase inhibitor (ARI) for the treatment of Galactosemia, a rare pediatric metabolic disease.